Product Description
GENV-001 is a pre-clinical gene therapy that inhibits hemophilia arthropathy in animal models of the disease. Hemophilia Arthropathy is a progressive joint disease affecting 50% of hemophilia sufferers as a long-term consequence of repeated bleeding into the joints. (Sourced from: https://www.geneventiv.com/therapeutic-programs/)
Mechanisms of Action: Gene Therapy
Novel Mechanism: No
Modality: Gene Therapy
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: GeneVentiv
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 0: Oncology Hematological Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|
Recent News Events
Date |
Type |
Title |
|---|